Drugs that contain Adapalene; Benzoyl Peroxide
1. Epiduo patents expiration
EPIDUO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8241649 | GALDERMA LABS LP | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
Dec, 2022
(1 year, 4 months ago) | |
| US8809305 | GALDERMA LABS LP | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
Dec, 2022
(1 year, 4 months ago) | |
| US8105618 | GALDERMA LABS LP | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
Dec, 2022
(1 year, 4 months ago) | |
| US8936800 | GALDERMA LABS LP | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Dec, 2022
(1 year, 4 months ago) | |
| US7964202 | GALDERMA LABS LP | Method for treatment of common acne |
Sep, 2024
(4 months from now) | |
| US7820186 | GALDERMA LABS LP | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Nov, 2025
(1 year, 6 months from now) | |
| US8445543 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8080537 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8071644 | GALDERMA LABS LP | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| US8129362 | GALDERMA LABS LP | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 08, 2011 |
| New Patient Population(NPP) | Feb 01, 2016 |
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage
EPIDUO family patents
2. Epiduo Forte patents expiration
EPIDUO FORTE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8936800 | GALDERMA LABS | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Dec, 2022
(1 year, 4 months ago) | |
| US8809305 | GALDERMA LABS | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
Dec, 2022
(1 year, 4 months ago) | |
| US8445543 | GALDERMA LABS | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
Dec, 2022
(1 year, 4 months ago) | |
| US8909305 | GALDERMA LABS | Method and system for activating an application on a mobile device |
Dec, 2022
(1 year, 4 months ago) | |
| US8785420 | GALDERMA LABS | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
Dec, 2022
(1 year, 4 months ago) | |
| US9814690 | GALDERMA LABS | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Dec, 2022
(1 year, 4 months ago) | |
| US9387187 | GALDERMA LABS | Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
| US8729127 | GALDERMA LABS | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
| US8703820 | GALDERMA LABS | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
| US9381179 | GALDERMA LABS | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 15, 2018 |
Market Authorisation Date: 15 July, 2015
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
How can I launch a generic of EPIDUO FORTE before it's drug patent expiration?
More Information on Dosage
EPIDUO FORTE family patents